Skip to content

Three Quick Facts: Immupharma, Uru Metals, PPHE Hotel


Three things you need to know in the financial markets today from investment writer, Tony Cross.

#1. Immupharma interims show losses shrinking

Immupharma [LON:IMM] has released interim results today, noting perhaps most significantly that it has halved losses against the comparative period. Management note that they continue to make progress in terms of bringing late stage clinical assets through to final trial stage, with a drive to conclude further commercial and partnering deals.

#2. Uru Metals CLN maturity extended – again

Uru Metals [LON:URU] has announced that a CLN which had been due to mature yesterday has seen its term extended by two months. Other metrics remain unchanged. This isn’t the first time the loan term has been extended, but there’s no further supporting narrative.

#3. PPHE Hotel sees revenues well above pre-COVID levels

PPHE Hotel [LON:PPH] has issued results for the first six months of the year to 30th June. Total revenues advanced an eye catching 59% and stand some 15.9% above pre-pandemic levels. RevPAR stands materially above 2019 levels and the strength of trading means that management are recommending a return to historical capital distribution policies. FY23 results remain on track against previous guidance.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top